Biotech Values

[caravon]

mcbio,

Are there plans to amend ongoing P3 HCC to use capsule? Plans for another P3 NSCLC with capsule? Other trials with capsule?

These are good questions but is not clear what ARQL/Daiichi thinking is. What is perfectly clear that the ARQL/Daiichi decision making process is founded on guesses and speculations instead of on clinical data/results!

It was my impression that ARQL/Daiichi have a strong desire to move into the NSCLC even into front-line settings for specific subgroups.

PS
a) During the CC, Pucci had a very bad case of mouse diarrhea. He does not speak to a point.
b) I would like to here your take on the CC.